House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum.
By Ricardo Alonso-Zaldivar, Associated Press
Americans pay more for prescription drugs than any country in the world, and the pharmaceutical industry earns billions in profits each year. Critics blame pharmacy benefit managers, or PBMs, for a portion of those high costs through their role as…
By Megan Thompson, Mori Rothman
Federal agencies on Thursday announced charges in what Attorney General Jeff Sessions called “the largest health care fraud takedown in American history,” an investigation into over $2 billion in alleged fraud by doctors, pharmacists, and nurses.
By Lev Facher, STAT
Rushing to judgment is misguided. There are no quick fixes here, and while the Trump proposals are viewed as fatally flawed by many experts, they also include some worthy ideas.
By Philip Moeller
By Emily Kopp, Kaiser Health News
The cost of insulin medications has steadily risen over the past decade by nearly 300 percent.
By Sheila Kaplan, STAT
More than 1,300 lobbyists roamed the halls of Congress on the 21st Century Cures Act, and disclosure reports show most of them were working for pharmaceutical companies.
By Vikram Mansharamani
The superbug is a reminder of the unintended consequences of the modern quest for productivity. Barring a solution, it will take an enormous toll.
By Philip Moeller
The absence of drug-pricing proposals from the GOP contenders illustrates how hard it would be for Sanders or Clinton to get Congressional approval should they win office.
By PBS NewsHour
In our news wrap Thursday, embattled ex-Turing Pharmaceuticals CEO Martin Shkreli pleaded the Fifth when called to testify before Congress on drug pricing protocols. Also, 12.7 million Americans signed up for private health insurance under the Affordable Care Act this…
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.